Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)

Date

21 Oct 2023

Session

Poster session 10

Topics

Pathology/Molecular Biology;  Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Frank Sinicrope

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

F.A. Sinicrope1, G. Nelson2, B. Saberzadeh Ardestani3, G. Park4, Y. Lim5, D. Yan6, K. Shanmugam7, S. Alberts8, Q. Shi9, C. Ock10, R. Pai11, D. Segovia2

Author affiliations

  • 1 Oncology, Mayo Clinic, 55905 - Rochester/US
  • 2 Clinical Trials And Biostatistics, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 3 Gastroenterology, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 4 Oncology, Lunit Inc., 6247 - Seoul/KR
  • 5 Oncology, SNUH - Seoul National University Hospital, 03080 - Seoul/KR
  • 6 R&d, Roche Diagnostics - Research and Development, Informatics, 94002 - Belmont/US
  • 7 Cdma, Roche Diagnostics - Research and Development, Informatics, 94002 - Belmont/US
  • 8 Oncology, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 9 Hsr Department, Mayo Clinic, 55905 - Rochester/US
  • 10 Oncology Group, Medical Affairs, Lunit Inc., 6247 - Seoul/KR
  • 11 Pathology And Laboratory Medicine, Mayo Clinic - Arizona, 85054 - Arizona/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 569P

Background

Artificial intelligence (AI) algorithms have been developed to distinguish MMR-D from MMR-P (proficient) tumors, yet they lack biological interpretability. To address this shortcoming, we used validated AI algorithms to detect and quantify well described morphological features in colon cancers from whole slide images.

Methods

Digital images of stage III colon carcinomas from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147; Alliance) were utilized. Available MMR-D (n=191) and randomly selected MMR-P (n=188) cancers were analyzed. QuantCRC quantifies the amount of stroma and stromal subtypes (immature, mature, inflammatory) and tumor/stroma ratio in addition to grade, mucin, signet ring cells, budding/poorly differentiated clusters (TB/PDC) and tumor-infiltrating lymphocytes (TILs). We also distinguished TILs in epithelium vs stromal using another AI algorithm (Lunit SCOPE IO). Area under the curve (AUC), i.e., discrimination threshold, was measured for each feature to predict MMR status.

Results

Among AI-derived morphological features, significant differences were found by MMR status whereby dMMR cancers had lower immature stroma but higher inflammatory stroma, higher tumor grade, and increased mucin, signet ring cells, tumor size, TB/PDCs, and TILs (all Kruskal-Wallis p<0.05). Univariately, AUC (95% CI) values for prediction of MMR status above 0.6 were as follows: TILs 0.72 (0.67-0.77), immature stroma 0.67 (0.62-0.73); inflammatory stroma 0.67 (0.62-0.73); tumor grade 0.65 (0.60-0.71); signet ring cells 0.65 (0.60-0.71); mucin 0.64 (0.59-0.70). Given that TILs in the overall tumor was most discriminant, we then utilized a TIL-specific AI algorithm measuring TILs in epithelium and stroma and found that epithelial TILs had a significantly higher AUC [ 0.79 (0.74-0.84) compared to stromal TILs 0.58 (0.52-0.63) p<0.0001].

Conclusions

Among morphological tumor features quantified by AI, tumor immature desmoplastic stroma and TILs, particularly epithelial TIL densities, were best able to distinguish MMR-D from MMR-P tumors. These findings have implications for prognosis and subtype-based interventions and can guide spatial molecular interrogation.

Clinical trial identification

NCT00079274.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Supported by Institutional grant support. NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS). Study NCCTG N0147 received funds from Sanofi.

Disclosure

G. Park, Y. Lim: Financial Interests, Institutional, Member: Lunit. D. Yan, K. Shanmugam: Financial Interests, Institutional, Full or part-time Employment: Roche. C-Y. Ock: Financial Interests, Institutional, Member: Lunit. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.